A publication for alumni, donors, faculty and friends of UC Davis Health

Volume 14 • No 2 • Fall 2017


They said it!

Julie Schweitzer, Ph.D.

School work is probably a lot less interesting than playing with the toy. You’re looking at competing activities here. It seems to me that it would be more distractive than helpful.”

Paul Knoepfler, Ph.D.

“They were just saying, ‘Screw the rules, we’re just going to set up shop and put up a website and start injecting people with stem cells.’ I saw that as a threat, first to patients, but to the field as well.”

John Olichney, M.D.

“We have a real knowledge gap in accurately knowing if dementia is different in minorities as compared to whites.”

Simon Cherry, Ph.D.

It will allow (pharmaceutical researchers) not just to ask, ‘Is my drug reaching a tumor?’ but ‘How much is in the liver?’ for example. So it can help us identify the best drug candidates, and we can hopefully have fewer failures in clinical trials.”

Jan Nolta, Ph.D.

The issue of so-called clinics offering unauthorized therapies that are listed on ClinicalTrials.gov is a big problem. Patients are led to believe that this listing makes the trials legitimate, but in fact it does not.”